semaglutide approved for cardiovascular Weight loss drug reduces risk of adverse events by 20% among overweight, obese patients Long-Term SELECT Trial: Semaglutide Cuts

adults have reported heavy drinking at some point in their lives, few have sought treatment

The proportion of participants with serious adverse events (SAEs) was low in all treatment groups but was highest in the oral semaglutide 3 mg and sitagliptin 100 mg arms

Future large-scale clinical trials, such as SURPASS-CVOT and SUMMIT, are expected to further verify the long-term benefits of tirzepatide in cardiovascular health management, providing stronger evidence for its comprehensive treatment of diabetes and its complications

"Please don't be in such a rush to go and get these medications that aren't tested."Earlier this year, the Food and Drug Administration issued warnings about two companies making compounded versions of Mounjaro and Zepbound